---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-005466"
form_type: "8-K"
ticker: "CBDW"
cik: "0001877461"
company_name: "1606 CORP."
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:29:50.079626+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "medium"
source: SEC EDGAR
---

# 1606 Corp. signs non-binding LOI to acquire strategic stake in AI biotech Adnexus

## Summary
- LOI for a strategic stake in Adnexus, an AI biotech focused on early drug discovery and infectious disease research.
- Adnexus develops fully human monoclonal antibodies using immune B-cells from recovered HIV and SARS-COV-2 patients.
- Transaction subject to customary due diligence and conditions; no deal value or stake percentage disclosed.
- CEO Austen Lambrecht states the partnership aligns with expanding AI capabilities in healthcare.
- 1606 Corp. (OTC Pink: CBDW) will present at the 150th NIBA Show in Fort Lauderdale on August 5, 2024.

## SEC filing metadata
- accession: 0001477932-24-005466
- form_type: 8-K
- ticker: CBDW
- cik: 0001877461
- company_name: 1606 CORP.
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1877461/000147793224005466/0001477932-24-005466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1877461/000147793224005466/cbdw_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-005466
- JSON: https://secwatch.observer/filing/0001477932-24-005466.json
- Plain text: https://secwatch.observer/filing/0001477932-24-005466.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.